Rucaparib (Rubraca® ): interim data from Study CO-338-043 (ARIEL4) show a decrease in overall survival compared to standard of care

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Active substance
rucaparib camsylate
Therapeutic area (MeSH)
Ovarian Neoplasms
Procedure number
EMEA/H/A-20/1518/C/4272/0033
Regulatory outcome
Variation
DHPC type
Referral - Article 20 procedure
Referral name
Rubraca
Human ATC code
L01XX
Dissemination date
05/05/2022

How useful was this page?

Add your rating